Exact Sciences Stock Skyrockets on Old Colorectal Cancer Publication?
Exact Sciences (EXAS) stock shot up over 20% today as the company announced its stool DNA test study for the detection of colorectal cancer was approved for publication by a major gastroenterology journal, although the company fails to mention the name of the journal.
The study's results were previously announced at the Digestive Disease Week Conference back in May of 2006 which caused a big spike in the stock price. However, the stock continued the year long decline until just recently as the stock suddenly began a steep incline in late August. The question is now why? It surely cannot be due to today's announcement, since the study's results were previously announced; publication in a journal was just a matter of time!
Could there be some sort of a distribution or marketing deal to be announced soon perhaps?
Time will tell.
Exact Sciences (EXAS) stock shot up over 20% today as the company announced its stool DNA test study for the detection of colorectal cancer was approved for publication by a major gastroenterology journal, although the company fails to mention the name of the journal.
The study's results were previously announced at the Digestive Disease Week Conference back in May of 2006 which caused a big spike in the stock price. However, the stock continued the year long decline until just recently as the stock suddenly began a steep incline in late August. The question is now why? It surely cannot be due to today's announcement, since the study's results were previously announced; publication in a journal was just a matter of time!
Could there be some sort of a distribution or marketing deal to be announced soon perhaps?
Time will tell.
posted by Nico at
11:13 PM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home